Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
October 23, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Tenaya Therapeutics, Inc.
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in...
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
November 21, 2023 16:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
October 26, 2023 08:30 ET
|
Tenaya Therapeutics, Inc.
PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated...
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
October 09, 2023 08:30 ET
|
Tenaya Therapeutics, Inc.
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6...
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
October 05, 2023 08:30 ET
|
Tenaya Therapeutics, Inc.
Tenaya Therapeutics announced that the first patient has been dosed with TN-201 gene therapy.
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
October 02, 2023 17:30 ET
|
Tenaya Therapeutics, Inc.
Tenaya announced the publication of preclinical research in the October 3, 2023, issue of the American Heart Association’s journal, Circulation.
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
September 21, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
August 31, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 09, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401...